What is the primary driver behind Stryker's significant sales increase in the reported periods?

The primary driver is the acquisition of Howmedica, which was completed during this period. This acquisition contributed the majority of the reported sales growth, particularly in Orthopaedic Implants and MedSurg Equipment.

How did the Howmedica acquisition impact profitability, and what are the key non-recurring items investors should be aware of?

The Howmedica acquisition significantly impacted profitability due to non-recurring charges. These include inventory step-up adjustments totaling $57.3 million in Q3 and $185.2 million for the nine months, which increased the cost of sales. There were also increases in selling, general, and administrative expenses related to integration. These factors led to a reported net loss for the nine months and minimal net earnings for the quarter.

What is the significance of the 'pro forma' sales figures, and what do they indicate about the company's organic growth?

The pro forma sales figures provide a more normalized view by including Howmedica's sales for comparable prior periods. The consistent 10-11% growth on a pro forma basis, separate from the acquisition's immediate impact, indicates that Stryker's underlying business is also expanding organically through increased unit volume, other acquired businesses, and foreign currency effects.

What is the company's liquidity position and debt situation following the Howmedica acquisition?

Stryker's liquidity position remains relatively stable, with $102.5 million in cash and marketable securities. However, total long-term debt stands at $1,424.0 million, primarily due to borrowings to fund the Howmedica acquisition. The company believes its current cash, anticipated operational cash flows, and available borrowing capacity are sufficient to meet future obligations and debt repayments.

SYK 10-Q Quarterly Report Q3 FY1999 — Revenue, Net Income, EPS

Summary

Stryker Corporation reported significant growth in the third quarter and the first nine months of 1999, primarily driven by the acquisition of Howmedica. Total net sales surged by 91% in the third quarter and 98% for the first nine months compared to the prior year. The Howmedica acquisition accounted for a substantial portion of this growth, contributing 80% in the third quarter and 84% for the nine-month period. On a pro forma basis, which attempts to normalize for the acquisition, sales still showed healthy growth of 10% for the quarter and 11% for the nine months, indicating underlying organic expansion. Despite the topline growth, profitability was impacted by significant non-recurring charges related to the Howmedica integration. Cost of sales as a percentage of sales increased due to inventory step-up adjustments from the acquisition. Selling, general, and administrative expenses also rose significantly as a percentage of sales, largely attributed to the integration costs and a higher mix of orthopaedic implant sales. The company reported a net loss for the first nine months of 1999 and minimal net earnings for the third quarter, largely due to these acquisition-related charges. Excluding these non-recurring items, adjusted net earnings showed a modest increase. Investors should note the substantial increase in interest expense and intangibles amortization due to the Howmedica acquisition financing.

Key Highlights

1Total net sales increased by 91% to $498.9 million in Q3 1999 and 98% to $1,544.6 million in the first nine months of 1999.
2The Howmedica acquisition was the primary driver of sales growth, contributing 80% and 84% to the respective periods.
3Pro forma sales (excluding the immediate impact of Howmedica's purchase) showed a solid 10% increase in Q3 and 11% for the nine months, indicating underlying business growth.
4Cost of sales as a percentage of sales increased significantly due to $57.3 million in Q3 and $185.2 million in nine months of non-recurring inventory step-up costs from the Howmedica acquisition.
5Selling, general, and administrative expenses increased substantially, both in absolute terms and as a percentage of sales, due to acquisition-related costs and a higher mix of higher-cost orthopaedic implant sales.
6The company reported a net loss of $24.4 million for the first nine months of 1999 and net earnings of $0.1 million for Q3, heavily influenced by non-recurring charges.
7Excluding non-recurring charges, adjusted net earnings increased by 2% for the nine months and 8% for the third quarter, with adjusted EPS showing similar growth.

STRYKER CORP Quarterly Report (Amendment) for Q3 Ended Sep 30, 1999

Summary

Key Highlights

Frequently Asked Questions